GlassScriptPhysician profile
Jordan Christopher Smallwood
NPI 1902078066
$12,789.25
in general payments reported to CMS, 2019-2025
27 companies · $2,443 in 2025
The $2,443 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $19.33 · 2022: $110 · 2023: $2,141 · 2024: $7,801 · 2025: $2,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,986 · Consulting Fee: $5,365 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,986.45 |
| Consulting Fee | $5,365.02 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,088.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,856.74 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $985.67 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $985.04 | 2019-2025 | |
| Csl Behring | $819.39 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Amgen INC. | $602.99 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $389.32 | 2023-2025 | Cuvitru, Takhzyro, Hyqvia |
| Genentech USA, INC. | $341.94 | 2023-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $335.65 | 2022-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $308.92 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $193.87 | 2023-2025 | Orladeyo |
| Sanofi US Services INC. | $135.00 | 2025 | |
| Grifols USA, LLC | $111.95 | 2023-2025 | Xembify |
| Pfizer INC. | $102.03 | 2022-2025 | |
| Kaleo, INC. | $93.81 | 2019-2023 | Auvi-Q |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hospira, INC. | $91.71 | 2023-2024 | |
| Galderma Laboratories, L.P. | $80.86 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $55.49 | 2023-2025 | Ruconest |
| Blueprint Medicines Corporation | $39.41 | 2023-2025 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $31.19 | 2025 | Dawnzera |
| Merck Sharp & Dohme LLC | $30.36 | 2023 | |
| Paratek Pharmaceuticals, INC. | $28.12 | 2025 | Xhance |
| Janssen Biotech, INC. | $19.02 | 2023 | Imbruvica |
| Adma Biomanufacturing LLC | $16.52 | 2024 | |
| Organon LLC | $15.95 | 2025 | |
| Shire North American Group INC | $15.24 | 2019 | |
| Aytu Biopharma, INC. | $14.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Smallwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.